Tcw Group Inc Denali Therapeutics Inc. Transaction History

Tcw Group Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$20.63 - $30.17 $1.07 Million - $1.57 Million	51,953 Added 57.74%	141,924 $2.93 Million
Q2 2023 Aug 14, 2023	BUY	$23.37 - $32.96 $38,794 - $54,713	1,660 Added 1.88%	89,971 $2.66 Million
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $1.08 Million - $1.61 Million	49,280 Added 126.26%	88,311 $2.03 Million
Q4 2022 Feb 14, 2023	BUY	$26.28 - $33.92 $1.03 Million - $1.32 Million	39,031 New	39,031 $1.09 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Tcw Group Inc, based on Form 13F filings with the SEC.

Stay updated on Tcw Group Inc with notifications on news.